Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis.

Prabalini Rajendram,Gretchen L Sacha,Omar Mehkri,Xiaofeng Wang,Xiaozhen Han,Vidula Vachharajani,Abhijit Duggal

Critical care explorations（2021）

引用 12|浏览1

暂无评分

摘要

Tocilizumab use was associated with a significant decrease in ICU mortality in critically ill coronavirus disease 2019 patients with severe hypoxemic respiratory failure. Future randomized controlled trials limited to tocilizumab administration in critically ill coronavirus disease 2019 patients, with severe hypoxemic respiratory failure, are needed to support these findings.

查看译文

关键词

acute hypoxemic respiratory failure,coronavirus disease 2019 critical illness,cytokine storm,tocilizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要